A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
Primary Purpose
Obesity
Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
Diet and Exercise
orlistat [Xenical]
Sponsored by

About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- adolescent patients, 12-14 years of age
- overweight or obese
Exclusion Criteria:
- age <12 or >14 years
- BMI in normal range
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Change in BMI
Secondary Outcome Measures
Adverse events, laboratory parameters
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00940628
Brief Title
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
Official Title
Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive Xenical 120mg po tid. The anticipated time on study treatment is 1 year, and the target sample size is <100 individuals.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Other
Intervention Type
Behavioral
Intervention Name(s)
Diet and Exercise
Intervention Description
mildly hypocaloric diet and physical exercise
Intervention Type
Drug
Intervention Name(s)
orlistat [Xenical]
Intervention Description
120mg po tid
Primary Outcome Measure Information:
Title
Change in BMI
Time Frame
At each clinic visit, every 4 weeks
Secondary Outcome Measure Information:
Title
Adverse events, laboratory parameters
Time Frame
At each clinic visit, every 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adolescent patients, 12-14 years of age
overweight or obese
Exclusion Criteria:
age <12 or >14 years
BMI in normal range
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Ekaterinburg
ZIP/Postal Code
620028
Country
Russian Federation
City
Kazan
ZIP/Postal Code
420073
Country
Russian Federation
City
Khabarovsk
ZIP/Postal Code
680063
Country
Russian Federation
City
Krasnodar
ZIP/Postal Code
350013
Country
Russian Federation
City
Krasnoyarsk
ZIP/Postal Code
660074
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117036
Country
Russian Federation
City
Nizhny Novgorod
ZIP/Postal Code
603136
Country
Russian Federation
City
Novosibirsk
ZIP/Postal Code
630048
Country
Russian Federation
City
Samara
ZIP/Postal Code
443079
Country
Russian Federation
City
Tumen
ZIP/Postal Code
625023
Country
Russian Federation
City
Yaroslavl
ZIP/Postal Code
150030
Country
Russian Federation
12. IPD Sharing Statement
Learn more about this trial
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
We'll reach out to this number within 24 hrs